Abstract
Background The lack of approved treatments for the majority of rare diseases is reflective of the unique challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are needed to render the development process more feasible and appropriate for these rare populations, and thereby expedite the approval of promising treatments to address patients’ high unmet medical need. Here, we describe the development of an innovative master protocol and primary outcome assessment to investigate the modified amino acid N-acetyl-L-leucine (Sponsor Code: IB1001) in three seperate, multinational, phase II trials for three ultra-rare, autosomal-recessive, neurodegenerative disorders: Niemann-Pick disease type C (NPC), GM2 Gangliosidoses (Tay-Sachs and Sandhoff disease; “GM2”), and Ataxia Telangiectasia (A-T).
Methods/design The innovative IB1001 master protocol and novel CI-CS primary endpoints were developed through a close collaboration between the Industry Sponsor, Key Opinion Leaders, representatives of the Patient Communities, and National Regulatory Authorities. As a result, the open-label, rater-blinded study design is considerate of the practical limitations of recruitment and retention of subjects in these ultra-orphan populations. The novel primary endpoint, the Clinical Impression of Change in Severity© (CI-CS), accommodates the heterogenous clinical presentation of NPC, GM2, and A-T: at screening, the Principal Investigator appoints for each patient a primary anchor test (either the 8 Meter Walk Test (8MWT) or 9 Hole Peg Test of the Dominant Hand (9HPT-D)) based on his/her unique clinical symptoms. The anchor tests are videoed in a standardized manner at each visit to capture all aspects related to the patient’s functional performance. The CI-CS assessment is ultimately performed by independent, blinded raters who compare videos of the primary anchor test from three periods: baseline, the end of treatment, and the end of a post-treatment washout. Blinded to the timepoint of each video, the raters make an objective comparison scored on a 7-point Likert scale of the change in the severity of the patient’s neurological signs and symptoms from Video A to Video B. To investigate both the symptomatic and disease-modifying effects of treatment, N-acetyl-L-leucine is assessed during two treatment sequences: a 6-week parent study, and one-year extension phase.
Discussion The novel CI-CS assessment, developed through a collaboration of all stakeholders, is advantageous in that it better ensures the primary endpoint is functionally relevant for each patient, is able to capture small but meaningful clinical changes critical to the patients’ quality of life (fine-motor skills; gait), and blinds the primary outcome assessment. The results of these three trials will inform whether N-acetyl-L-leucine is an effective treatment for NPC, GM2, and A-T, and can also serve as a new therapeutic paradigm for the development of future treatments for other orphan diseases.
Trial registrations The three trials (IB1001-201 for Niemann-Pick disease type C (NPC); IB1001-202 for GM2 Gangliosidoses (Tay-Sachs and Sandhoff); IB1001-203 for Ataxia-Telangiectasia (A-T)) have been registered at www.clinicaltrials.gov (NCT03759639; NCT03759665; NCT03759678), www.clinicaltrialsregister.eu (EudraCT: 2018-004331-71; 2018-004406-25; 2018-004407-39) and https://www.germanctr.de (DR KS-ID: DRKS00016567; DRKS00017539; DRKS00020511).
Competing Interest Statement
MF is a co-founder, shareholder, and Chairman of IntraBio. TF and IB are officers and shareholders of IntraBio. FP is a cofounder, shareholder, and consultant to IntraBio and consultant to Actelion and Orphazyme. MS is a shareholder to IntraBio, and consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion; he has received speaker's honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, Johnson & Johnson, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. AG and GC are cofounders, shareholders and consultants to IntraBio. MP is a shareholder of IntraBio, and has received consulting fees, honoraria and research grants from Actelion Pharmaceuticals Ltd. and Biomarin. CV, SF are consultants and shareholders of IntraBio. UG, TM, GB, and RKay are consultants to IntraBio. TBE received honoraria for lecturing from Actelion and Sanofi Genzyme. IntraBio owns patents EP3359146 and EP3416631 (related to treatment of lysosomal storage disorders and neurodegenerative diseases with Acetyl-Leucine and its analogues). IntraBio has pending patent applications EP19174007.5, EP3482754, PCT/US2018/056420, PCT/US2018/018420, PCT/IB2018/054676, PCT/IB2019/051214, PCT/IB2017/054928, PCT/GB2017/051090, PCT/IB2017/054929, USPTO 62/812,987, USPTO 62/842,296, USPTO 62/888,894, USPTO 62/895,144, USPTO 62/868,383, USPTO 62/931,003, USPTO 62/960,637, and PCT/IB2019/060525 relating to treatment of lysosomal storage disorders, neurodegenerative diseases and neurodegeneration with Acetyl-leucine and its analogues.
Clinical Trial
www.clinicaltrials.gov (NCT03759639; NCT03759665; NCT03759678); www.clinicaltrialsregister.eu (EudraCT: 2018-004331-71; 2018-004406-25; 2018-004407-39); and https://www.germanctr.de (DR KS-ID: DRKS00016567; DRKS00017539; DRKS00020511)
Funding Statement
This study was financially supported by IntraBio (https://intrabio.com).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email addresses: tfields{at}intrabio.com, patterson.marc{at}mayo.edu, tatiana.bremova-ertl{at}extern.insel.ch, glynbelcher{at}pvconsult.co.uk, ian{at}intrabio.co.uk, grant.churchill{at}pharm.ox.ac.uk, william{at}atsociety.org.uk, will{at}npuk.org, sflint{at}intrabio.com, antony.galione{at}pharm.ox.ac.uk, granzer{at}granzer.biz, jgreenfield{at}ataxia.org.uk rick.karl{at}curetay-sachs.org, richard.kay{at}rkstatistics.com, dan{at}cats-foundation.org, toni.mathieson{at}inpda.org, meyer{at}granzer.biz, diana{at}ntsad.org, frances.platt{at}pharm.ox.ac.uk, lincoln.tsang{at}arnoldporter.com, cverburg{at}intrabio.com, mfactor{at}intrabio.com, michael.Strupp{at}med.uni-muenchen.de
Data Availability
Not applicable as the study is a trial design and data will be published after the trials are complete.
List of abbreviations
- 8MWT
- 8-meter walk test
- 9HPT-D
- 9-hole peg test of the dominant hand
- A-T
- Ataxia Telangiectasia
- CI-CS
- clinical impression of change in severity
- CI-S
- clinical impression of severity
- DSMB
- Data Safety Monitoring Board
- EQ-QoL
- Euro Quality of Life
- EP
- Extension Phase
- FDA
- Food and Drug Administration
- GM2
- GM2 Gangliosidoses
- mITT
- modified intention to treat
- mDRS
- Modified Disability Rating Scale
- NPC
- Niemann-Pick type C
- NPC-CSS
- NPC clinical severity scale
- PI
- principal investigator
- SARA
- Scale for the Assessment and Rating of Ataxia
- SCAFI
- Spinocerebellar Ataxia Functional Index.